Somewhat Favorable Media Coverage Somewhat Unlikely to Impact MacroGenics (MGNX) Stock Price

Media headlines about MacroGenics (NASDAQ:MGNX) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MacroGenics earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.4648659011379 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

Shares of MacroGenics (NASDAQ MGNX) traded up $0.13 during trading hours on Tuesday, hitting $29.32. The company had a trading volume of 169,046 shares, compared to its average volume of 268,222. The firm has a market cap of $1,096.12, a P/E ratio of -41.89 and a beta of 2.52. MacroGenics has a 1 year low of $14.36 and a 1 year high of $32.74.

Several brokerages recently commented on MGNX. Morgan Stanley reaffirmed an “equal weight” rating and issued a $26.00 price objective (up from $18.00) on shares of MacroGenics in a research report on Wednesday, March 14th. BidaskClub upgraded shares of MacroGenics from a “hold” rating to a “buy” rating in a report on Thursday, March 8th. Zacks Investment Research cut shares of MacroGenics from a “hold” rating to a “sell” rating in a research note on Tuesday, February 6th. HC Wainwright began coverage on shares of MacroGenics in a research note on Monday, March 5th. They issued a “buy” rating and a $38.00 price target on the stock. Finally, Cowen reissued a “buy” rating on shares of MacroGenics in a research note on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $29.78.

In other news, SVP Eric Blasius Risser sold 1,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $25.01, for a total transaction of $25,010.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Lynn Cilinski sold 23,967 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $25.01, for a total value of $599,414.67. The disclosure for this sale can be found here. Insiders have sold a total of 42,967 shares of company stock valued at $1,098,005 over the last three months. Corporate insiders own 8.30% of the company’s stock.

WARNING: This article was first reported by BBNS and is the property of of BBNS. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/2018/03/20/macrogenics-mgnx-getting-somewhat-favorable-news-coverage-study-shows/1920111.html.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Insider Buying and Selling by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Didi Gregorius Starts Season Hot at the Plate
Didi Gregorius Starts Season Hot at the Plate
Andujar, Stanton and Torres Shine in Yankees Rout
Andujar, Stanton and Torres Shine in Yankees Rout
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox


Leave a Reply

 
© 2006-2018 BBNS.